Back to top
more

Intrexon Corporation (XON)

(Delayed Data from NSDQ)

$4.51 USD

4.51
2,693,644

+0.29 (6.87%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.50 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA

by Zacks Equity Research

The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).

Is the Options Market Predicting a Spike in Intrexon (XON) Stock?

by Zacks Equity Research

Investors need to pay close attention to Intrexon (XON) stock based on the movements in the options market lately.

Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3

by Zacks Equity Research

Intrexon (XON) posts a narrower-than-expected loss and misses sales estimates in the third quarter of 2019.

Teladoc Gains on Growing Acceptance for TeleHealth Services

by Zacks Equity Research

Teladoc's (TDOC) extensive ecosystem and infrastructure poise it well for long-term growth in the expanding telehealth industry.

Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2

by Zacks Equity Research

Intrexon (XON) posts a narrower-than-expected loss and misses sales estimates in the second quarter of 2019.

Earnings Preview: Intrexon (XON) Q2 Earnings Expected to Decline

by Zacks Equity Research

Intrexon (XON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Intrexon (XON) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Intrexon (XON) stock based on the movements in the options market lately.

Intrexon Up on Striking 100M Cannabinoid Deal With Surterra

by Zacks Equity Research

Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.

Intrexon (XON) Up 24.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Fibrocell Up on FDA Designation for Gene Therapy Candidate

by Zacks Equity Research

Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.

Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues

by Zacks Equity Research

Intrexon (XON) reports in line loss in the first quarter of 2019. Also, sales miss estimates.

Analysts Estimate Intrexon (XON) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Intrexon (XON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fibrocell (FCSC) Q1 Earnings: What's in Store for the Stock?

by Zacks Equity Research

For Fibrocell's (FCSC) Q1, investors will eye the company's progress with its gene therapy candidate, FCX-007, currently being developed for treating recessive dystrophic epidermolysis bullosa.

Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises

by Zacks Equity Research

Fibrocell (FCSC) collaborates with Castle Creek to develop/commercialize its gene therapy candidate, FCX-007, for the rare skin disease of recessive dystrophic epidermolysis bullosa. Stock jumps.

    Why Is Intrexon (XON) Down 34% Since Last Earnings Report?

    by Zacks Equity Research

    Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4

    by Zacks Equity Research

    Intrexon (XON) incurs narrower-than-expected loss in the fourth quarter of 2018.

    Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds

    by Zacks Equity Research

    Merck KGaA (MKGAF) inks an exclusive licensing agreement with Vertex for two DNA-dependent protein kinase inhibitors in the field of gene editing for six specific genetic disease indications.

    Intrexon Signs Licensing Agreement with Next Green Wave

    by Zacks Equity Research

    Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.

    Do Options Traders Know Something About Intrexon (XON) Stock We Don't?

    by Zacks Equity Research

    Investors need to pay close attention to Intrexon (XON) stock based on the movements in the options market lately.

    Why Is Intrexon (XON) Down 31.5% Since Last Earnings Report?

    by Zacks Equity Research

    Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3

    by Zacks Equity Research

    Intrexon (XON) incurs narrower-than-expected loss, while revenues miss estimates in the third quarter of 2018.

    Analysts Estimate Intrexon (XON) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Intrexon (XON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Implied Volatility Surging for Intrexon (XON) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to Intrexon (XON) stock based on the movements in the options market lately.

      Ryan McQueeney headshot

      Merger Mania: Examining the Latest M&A News & Trends | Free Lunch

      by Ryan McQueeney

      Ryan McQueeney breaks down the latest merger & acquisition news involving Comcast and Sky, Pandora and Sirius XM, and Barrick Gold and Randgold Resources. He also highlights an interesting new marijuana play from biotech DNA expert Intrexon. Later, he discusses recent M&A trends and data.

        Intrexon Reports Preliminary Earnings and Revenues for Q2

        by Zacks Equity Research

        Intrexon (XON) reports preliminary second-quarter 2018 results and expects a loss of 17 cents for the quarter.